Open access research
Aleth (from the Greek for pure truth) is an open-access research platform focused on scientific innovation across life sciences, AI, and deep tech. Built AI-native with rigorous human oversight of the research process.
This site hosts our permanent research archive, while the live insights drop directly into your inbox. Subscribe for free via Substack to get our latest life sciences, AI and deep tech analysis the moment it’s published. Subscribe free at sub.aleth.co (opens in new tab)
ALETH / NOTES
Ellison's EIT to invest an extra $1.2bn in Oxford
Pharma stocks add $440bn after pricing deal
Genmab to buy Dutch biotech Merus for $8bn
UniQure gene therapy slows Huntington's
GSK to invest $30bn in the US
Merck scraps its $1bn+ London lab
AstraZeneca cracks resistant hypertension
Britain's drug pricing talks collapse
US and EU cap pharma tariffs at 15%
US biotech goes six months without an IPO
Lilly's obesity pill misses, Novo rebounds
Novo Nordisk loses its obesity lead
AstraZeneca pledges $50bn to the US
Eight UK babies born from three-person IVF
Merck buys UK'S Verona Pharma for $10bn
AstraZeneca eyes quitting London listing for US
GP surgeries start prescribing Mounjaro
* * *
Subscribe for free to receive in your inbox at: sub.aleth.co (opens in new tab).